iMOS® competes against pathogenic bacteria for host cell binding sites
There are many mannose-modified glycoproteins on the surface of human cells. Recent studies have found that pathogenic bacteria, such as Escherichia coli (E.coli), can bind to human cells through the binding of FimH protein at the end of pilus to mannose of glycoprotein. iMOS® competes for the binding of FimH of E.coli, which abolishes their colonization. Thus, it acts as an antibiotic replacement for the treatment of infections (Fig.4)
Fig.4 iMOS® competes against pathogenic bacteria for host cell binding sites
Ref: Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Spaulding CN et al. 2017.Nature 546:528-532.